Medicament composition comprising Enalapril quick-releasing part and felodipine slow-releasing part

Abstract

The invention relates to a medicament composition preparation comprising an Enalapril quick-releasing part and a felodipine slow-releasing part. The medicament composition is a medical composition formed by mixing Enalapril and felodipine as medical active components with and pharmaceutically acceptable auxiliary materials. The composition preparation comprising comprises a slow-releasing part tablet core and a quick-releasing part coating, wherein the slow-releasing part tablet core is the felodipine, and the quick-releasing part coating is the Enalapril or Enalapril-acid addition salts. Thecomposition can rapidly stabilize blood pressure and permanently keep the blood pressure steady.

Description

technical field [0001] The invention relates to a pharmaceutical composition preparation for treating hypertension, in particular to an immediate-release part coating layer containing enalapril or enalapril-acid addition salt and a sustained-release part containing felodipine The pharmaceutical composition preparation of tablet core belongs to the technical field of medicine. Background technique [0002] Enalapril is an angiotensin-converting enzyme (ACE) inhibitor. After oral administration, it is hydrolyzed into dicarboxylic acid enalaprilat in the liver, which strongly inhibits angiotensin-converting enzyme, reduces the content of angiotensin II, and causes systemic vascular Diastole, blood pressure drops. The usual dose is 5-10 mg, and it must be injected intravenously in order to speed up the onset time. The medicine treats moderate or severe hypertension, and the dose must be increased to 80mg / day, and only about 60% of hypertensive patients can be effective when us...

AI Technical Summary

Problems solved by technology

Enalapril was first developed by Merck Company of the United States, and it was launched in the Federal Republic of Germany in 1984. It was once one of the best-selling prescription drugs in the European and American markets, but sales began to decline after 2001. The main reasons are: The patent expires, countries imitate one after another, new products of the same kind appear continuously, and there are some problems: (1) The antihypertensive curative effect has a certain limit, and a large number of literature reports have a total effective rate of only about 60%, and 40% are ineffective or have no significant curative effect; ( 2) There is no obvious advantage in target organ protection

[0005] The two drugs have been widely used in the treatment of cardiovascular diseases. There are domestic reports on compositions and preparation methods containing dihydropyridine calcium antagonists and angiotensin-converting enzyme inhibitors (see CN101548973), but the patent uses The two kinds of excipients are used as the sustained-release matrix, and a more complicated process must be adopted. Organic solvents must be used in the coating process, which has high production costs and is not conducive to large-scale production and environmental protection.

Images